Close
Help




JOURNAL

Ophthalmology and Eye Diseases

Bevasiranib for the Treatment of Wet, Age-Related Macular Degeneration

Submit a Paper


Ophthalmology and Eye Diseases 2010:2 75-83

Review

Published on 19 Dec 2010

DOI: 10.4137/OED.S4878


Further metadata provided in PDF



Sign up for email alerts to receive notifications of new articles published in Ophthalmology and Eye Diseases

Abstract

Age- related Macular Degeneration (AMD) is the leading cause of severe visual impairment in people 65 years and older in industrialized nations. Exudative, or “wet”, AMD is a late form of AMD (as distinguished from atrophic, so-called dry, AMD) and is responsible for over 60% of all cases of blindness due to AMD. It is widely accepted that vascular endothelial growth factor (VEGF) is a key component in the pathogenesis of choroidal neo-vascularization (CNV), which is a precursor to wet AMD. The current gold-standard for treating wet AMD is the monoclonal antibody fragment ranibizumab (trade name Lucentis), which targets VEGF. Other agents used to treat wet AMD include pegaptanib (Macugen), bevacizumab (Avastin; off-label use), and several other experimental agents. The advent of small interfering RNA (siRNA) has presented a whole new approach to inhibiting VEGF. This article reviews the status of a novel siRNA-based therapeutic, bevasiranib, for the treatment of wet AMD. Bevasiranib is believed to work by down regulating VEGF production in the retina. Studies in human cell-lines and animal models have shown that VEGF siRNAs are effective in inhibiting VEGF production. Although there is a lack of sufficient published data on human studies supporting the use of bevasiranib for wet AMD, available data indicates that due to its unique mechanism of action, bevasiranib might hold some promise as a primary or adjunct treatment for wet AMD.



Downloads

PDF  (482.05 KB PDF FORMAT)

RIS citation   (ENDNOTE, REFERENCE MANAGER, PROCITE, REFWORKS)

BibTex citation   (BIBDESK, LATEX)

XML




What Your Colleagues Say About Ophthalmology and Eye Diseases
The publishing process was fast and convenient.  The journal staff were extremely helpful and prompt in responding to questions and issues related to the submission.  The online submission and revision process was easy and staff were readily available to answer any questions.  The reviewers' comments were insightful, very constructive and extremely helpful.  The author interface is user-friendly. The publishing process is fast and convenient.  I highly recommend others practitioners and researchers to consider this journal ...
Dr Elena Pacella (Sapienza University of Rome, Italy)
More Testimonials

Quick Links


New article and journal news notification services